Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact Us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Latest published research
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Services for private Companies
Tax enhanced research
Product reports for investors and advisors.
Bespoke consulting services
Bespoke services
Services for clients with specific needs
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
24: Making big ideas investible and measuring impact | Dan Somers of Boundary Capital
Stay up-to-date with the latest research
Sign up to our newsletter
COVID-19: -
Our Commitment to Client Service & Investor Communications
Latest research
Our research can still be accessed for free under MIFID II.
Find out more >
All research
Corporate research
- Update
- Monthly Report
- Sector Report
Tax enhanced research
- VCT
- EIS
- SEIS
- Initiation
All sectors
Agriculture
Building & Construction
Consumer
Financials
Industrial
Infrastructure
Investment Companies
Life Sciences
Media
Mining
Oil & Gas
Property
Renewables
Services
Technology
Transportation
Utilities
List companies
Avacta Group plc
Life Sciences
Wake-up call for the market
By
Dr Gregoire Pave
10 Dec 2018
Gateley Plc
Services
Strong trading and industry opportunity
By
Steve Clapham
07 Dec 2018
Non-Standard Finance
Financials
Reading the runes: strong, controlled growth
By
Mark Thomas
05 Dec 2018
Redx Pharma
Life Sciences
RXC006: first anti-fibrosis development candidate
By
Dr Martin Hall
30 Nov 2018
Palace Capital
Property
Interim results to September 2018 reported
By
Mike Foster
28 Nov 2018
Redx Pharma
Life Sciences
Streamlined, focused and good value
By
Dr Gregoire Pave
27 Nov 2018
The 600 Group
Industrial
Trading still healthy, with good order book
By
Paul Singer
20 Nov 2018
Titon Holdings
Building & Construction
My Aim is True
By
Tony Williams
15 Nov 2018
Chronix Biomedical
Life Sciences
Monitoring treatment, improving outcomes
By
Dr Dorothea Hill
13 Nov 2018
Haydale Graphene Industries Plc
Industrial
Enlightenment delayed
By
Paul Singer
12 Nov 2018
Redx Pharma
Life Sciences
ROCK2 inhibitors in chronic kidney disease
By
Dr Gregoire Pave
09 Nov 2018
Prev
1
...
30
31
32
33
34
...
52
Next
